JP2023502323A - 抗ｔｉｇｉｔ抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法 - Google Patents

抗ｔｉｇｉｔ抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法 Download PDF

Info

Publication number
JP2023502323A
JP2023502323A JP2022524620A JP2022524620A JP2023502323A JP 2023502323 A JP2023502323 A JP 2023502323A JP 2022524620 A JP2022524620 A JP 2022524620A JP 2022524620 A JP2022524620 A JP 2022524620A JP 2023502323 A JP2023502323 A JP 2023502323A
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
chain variable
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502323A5 (https=
JPWO2021098757A5 (https=
Inventor
ジアン、ベイベイ
リウ、イェ
ソン、シャオミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
BeOne Medicines Ltd
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeOne Medicines Ltd, Beigene Ltd filed Critical BeOne Medicines Ltd
Publication of JP2023502323A publication Critical patent/JP2023502323A/ja
Publication of JP2023502323A5 publication Critical patent/JP2023502323A5/ja
Publication of JPWO2021098757A5 publication Critical patent/JPWO2021098757A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022524620A 2019-11-21 2020-11-19 抗ｔｉｇｉｔ抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法 Pending JP2023502323A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/120033 2019-11-21
CN2019120033 2019-11-21
PCT/CN2020/129992 WO2021098757A1 (en) 2019-11-21 2020-11-19 Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies

Publications (3)

Publication Number Publication Date
JP2023502323A true JP2023502323A (ja) 2023-01-24
JP2023502323A5 JP2023502323A5 (https=) 2023-11-29
JPWO2021098757A5 JPWO2021098757A5 (https=) 2023-11-29

Family

ID=75980305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524620A Pending JP2023502323A (ja) 2019-11-21 2020-11-19 抗ｔｉｇｉｔ抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法

Country Status (12)

Country Link
US (1) US20230002500A1 (https=)
EP (1) EP4061846A4 (https=)
JP (1) JP2023502323A (https=)
KR (1) KR20220103709A (https=)
CN (1) CN114746446A (https=)
AU (1) AU2020385499A1 (https=)
BR (1) BR112022009265A2 (https=)
CA (1) CA3157042A1 (https=)
IL (1) IL293118A (https=)
MX (1) MX2022006148A (https=)
WO (1) WO2021098757A1 (https=)
ZA (1) ZA202204422B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
AU2023305697A1 (en) * 2022-07-15 2025-02-20 Beigene Switzerland Gmbh Methods of cancer treatment using anti-tigit antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515544A (ja) * 2013-03-18 2016-05-30 バイオセルオーエックス プロダクツ ビー．ブイ． ヒト化抗ｃｄ１３４（ｏｘ４０）抗体およびその使用
WO2017077085A2 (en) * 2015-11-04 2017-05-11 Cancer Research Technology Immunomodulatory antibodies
WO2019089921A1 (en) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
WO2019129261A1 (en) * 2017-12-30 2019-07-04 Beigene, Ltd. Anti-tigit antibodies and their use as therapeutics and diagnostics
WO2019223733A1 (en) * 2018-05-23 2019-11-28 Beigene, Ltd. Anti-ox40 antibodies and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EP3208612B1 (en) * 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
KR20170072343A (ko) * 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
TN2019000101A1 (en) * 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
KR102769109B1 (ko) * 2017-11-24 2025-02-18 유큐(베이징) 바이오파마 코., 엘티디 항―ｏｘ４０ 항체 및 그의 용도
CN110092832B (zh) * 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515544A (ja) * 2013-03-18 2016-05-30 バイオセルオーエックス プロダクツ ビー．ブイ． ヒト化抗ｃｄ１３４（ｏｘ４０）抗体およびその使用
WO2017077085A2 (en) * 2015-11-04 2017-05-11 Cancer Research Technology Immunomodulatory antibodies
WO2019089921A1 (en) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
WO2019129261A1 (en) * 2017-12-30 2019-07-04 Beigene, Ltd. Anti-tigit antibodies and their use as therapeutics and diagnostics
WO2019223733A1 (en) * 2018-05-23 2019-11-28 Beigene, Ltd. Anti-ox40 antibodies and methods of use

Also Published As

Publication number Publication date
CN114746446A (zh) 2022-07-12
IL293118A (en) 2022-07-01
MX2022006148A (es) 2022-08-17
BR112022009265A2 (pt) 2022-08-02
WO2021098757A1 (en) 2021-05-27
KR20220103709A (ko) 2022-07-22
US20230002500A1 (en) 2023-01-05
EP4061846A4 (en) 2023-12-20
EP4061846A1 (en) 2022-09-28
CA3157042A1 (en) 2021-05-27
ZA202204422B (en) 2023-05-31
AU2020385499A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
JP7489922B2 (ja) 抗ｏｘ４０抗体及び使用方法
WO2021098774A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
WO2021098757A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
JP2023503229A (ja) 抗ｏｘ４０抗体とマルチキナーゼ阻害剤とによる癌の治療
JP2023503230A (ja) Ｐｉ３キナーゼデルタ阻害剤との組合せで抗ｏｘ４０抗体を用いる癌治療の方法
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
WO2021098748A1 (en) Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents
CA3100766C (en) Anti-ox40 antibodies and methods of use
EA046633B1 (ru) Способы лечения рака с применением антител к ox40 в комбинации с антителами к tigit
EA047307B1 (ru) Способы лечения рака с применением антител к ox40 в комбинации с антителами к tim3
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
HK40076665A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
HK40050839A (en) Anti-ox40 antibodies and methods of use
EA045547B1 (ru) Антитела к ox40 и способы применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250708